Decision Expected Soon on Fate of Pradaxa Bleeding Lawsuits

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa Diagram
Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Orlando, FL (PRWEB) July 31, 2012

The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have suffered internal bleeding after taking the drug Pradaxa that a federal panel will soon decide whether the claims filed by victims will be consolidated under one court, and where that court will be located.

Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular blood thinning drug prescribed to prevent strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, Pradaxa has sold over $1 billion in the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

On December 7, 2011, however, the FDA warned hundreds of thousands of patients that it was investigating the safety of Pradaxa after receiving more injury or death reports from the drug than expected. The Institute for Safe Medication Practices also reported on June 6, 2012 that Pradaxa led all other medications in 2011 for reports to the FDA of death or bleeding.

Due to the number of lawsuits expected over Pradaxa bleeding injury or death, lawyers filed a motion on May 30, 2012 requesting that all cases be moved to one central federal court. The case is known as MDL No. 2385 IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. In the motion, lawyers state they expect as many as 500 Pradaxa lawsuits will be filed.

The United States Judicial Panel on Multidistrict Litigation (JPML) heard arguments from lawyers representing victims and the manufacturer, Boehringer Ingelheim, on July 26, 2012. A decision is expected soon on whether the cases will be consolidated, and where.

The Pradaxa Resource Center believes moving all Pradaxa lawsuits into one federal court will expedite the litigation process and help victims share in valuable evidence. However, due to the specialized nature of these federal MDL cases, victims should make sure any lawyer they choose has experience in this type of litigation.

Anyone affected by Pradaxa side effects is urged to speak with a lawyer about their legal options. The Pradaxa Resource center works only with lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.


Contact